Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Assay Allows Individualized Chemotherapy Management Monitoring

By HospiMedica staff writers
Posted on 01 Jul 2008
The 5-FU Personalized Chemotherapy Management (PCM) assay, intended for use on the Olympus AU400 clinical chemistry analyzer, allows oncologists who prescribe 5-fluorouracil (5-FU) continuous infusion regimens (alone or in combination for colorectal, stomach, breast, and pancreatic cancers) to control and fine-tune individualized dosing. More...
Recent results from a Phase III randomized study compared colorectal cancer patients who were dosed with 5-FU based on body surface area (BSA, the current standard dosing method) with patients whose dose was adjusted based on the actual concentration of 5-FU in blood plasma. The study results showed that response rates among monitored patients doubled; two-year overall survival improved by 48%; and toxic side effects were significantly lower. Additionally, only 25% of BSA dosed patients were found to be in the target range to receive the optimal therapeutic benefit; 58% of patients were found to be under-dosed and had doses adjusted upward, while 17% were found to be over-dosed, increasing the risk of severe side effects. The study was published in the May 2008 issue of the Journal of Clinical Oncology.

"The availability of the 5-FU PCM assay will give oncologists in the European Union a powerful, cost-effective tool in the battle against colorectal cancer,” said lead author Erick Gamelin, M.D., Ph.D., director of the Paul Papin Cancer Center (Angers, France). "Our Phase III study demonstrates that the majority of patients are either over-dosed or in most cases, under-dosed. Personalized 5-FU dosing allows us to substantially reduce severe toxicity while improving patient quality of life and treatment outcomes.”

The 5-FU Personalized Chemotherapy Management assay system is a product of Saladax Biomedical (Bethlehem, PA, USA), and has received CE marking registration in the European Union (EU).

"Until now, a simple, rapid, and cost-effective 5-FU measurement tool that can be easily integrated into day-to-day practice has not been readily available. As a result, colorectal cancer patients receive chemotherapy based on their height and weight, with no monitoring system in place to allow oncologists to correlate dose with clinical patient response on an ongoing basis,” said Salvatore Salamone, Ph.D., CEO of Saladax Biomedical. "Access to this simple blood test will arm oncologists with the ability to individualize 5-FU dosing to ensure patients receive the optimal benefit from their treatment.”

Colorectal cancer is a worldwide public health problem, with more than 940,000 new cases diagnosed each year, resulting in approximately 500,000 deaths annually, according to data from the World Health Organization (WHO, Geneva, Switzerland). In the United States, colorectal cancer is the third leading cause of cancer mortality, and in 2008, nearly 50,000 deaths will be attributed to this disease. Data from industrialized countries demonstrate that incidence rates are strongly correlated with age, rising three-fold between the ages of 60 and 80 years.


Related Links:
Paul Papin Cancer Center
Saladax Biomedical

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.